HYDERABAD | 24 August 2026: Global biopharmaceutical solutions company Syneos Health has opened a new facility at Phoenix Equinox in Gachibowli, Hyderabad, strengthening the city’s position as a major hub for life sciences, clinical services, data and healthcare technology.

The facility is Syneos Health’s largest office in Asia and its third largest globally. The company is positioning the Hyderabad location as a strategic AI Hub, bringing together scientific expertise, biopharmaceutical knowledge and engineering capabilities to support AI-powered clinical development, safety and commercialization.

The expansion is significant because it places Hyderabad at the intersection of life sciences domain expertise and technology capabilities, a combination increasingly important as pharmaceutical companies adopt AI, advanced analytics and digital technologies across the drug-development and commercialization lifecycle.

KEY HIGHLIGHTS

  • Largest in Asia: The Hyderabad facility is Syneos Health’s largest office in Asia and third-largest globally.
  • AI at the Core: Syneos is positioning Hyderabad as an AI Hub focused on clinical development, safety and commercialization, combining scientific and engineering capabilities.
  • Multidisciplinary Capability: The company’s Hyderabad talent base spans clinical programming, pharmacovigilance, medical writing, transformation, product management, cybersecurity and data-related roles.
  • Life Sciences–Technology Convergence: The centre brings together biopharmaceutical expertise, data, engineering and AI, reflecting the increasing digitisation of drug development and healthcare services.
  • Global Delivery Role: The Hyderabad operation forms part of Syneos Health’s broader global network supporting biopharmaceutical companies across the clinical development and commercialization continuum.

Headquartered in Morrisville, North Carolina, Syneos Health is a privately held biopharmaceutical solutions organization formed in 2017 through the merger of INC Research and inVentiv Health. In September 2023, the enterprise was taken private in a $7.1 billion acquisition by an investment consortium comprising Elliott Investment Management, Patient Square Capital, and Veritas Capital. Operating as a dual Contract Research Organization (CRO) and Contract Commercial Organization (CCO), the company employs approximately 25,000 to 28,000 professionals across 110+ countries, delivering Phase I–IV clinical trial management, biostatistics, regulatory consulting, and healthcare commercialization services.

In India, the organization supports its worldwide clinical and data operations through delivery hubs in Bengaluru, Pune, Gurugram, and its newly expanded facility in Hyderabad, which serves as its largest operating center in Asia and third largest globally.

FROM CLINICAL SERVICES TO AI-ENABLED LIFE SCIENCES

The significance of Syneos Health’s Hyderabad expansion goes beyond the physical scale of the facility. Drug development is becoming increasingly data-intensive, with clinical research, safety, regulatory and commercial processes generating large and complex datasets. AI and advanced analytics are consequently becoming embedded across the biopharmaceutical value chain.

Syneos Health’s Hyderabad AI Hub is designed around this convergence. The company describes the location as bringing together scientific expertise, deep biopharmaceutical experience and modern engineering capabilities to accelerate the movement of therapies from development to patients.

The talent profile emerging around the Hyderabad operation reinforces this direction. Current Syneos roles in the city span clinical programming, clinical portfolio transformation, pharmacovigilance, medical writing, cybersecurity, product management and business operations indicative of a capability model that extends well beyond traditional clinical-support functions.

Industry Insights

Proofpoint’s expansion highlights several broader shifts in India’s capability-centre ecosystem:

  1. The Next Life Sciences GCC Is Multidisciplinary: The Syneos Health expansion illustrates how life sciences capability centres are moving beyond individual functions. Clinical expertise, data engineering, AI, pharmacovigilance, technology, transformation and commercial capabilities are increasingly converging within the same operating ecosystem.
  2. AI Is Moving Deeper into the Healthcare Value Chain: AI adoption in life sciences is expanding beyond generic enterprise automation. The Hyderabad hub is explicitly focused on applying AI across clinical development, safety and commercialization. This creates demand for talent that understands both the technology and the underlying scientific context.
  3. Domain Depth Is Becoming a GCC Differentiator: For life sciences companies, access to generic technology talent is no longer sufficient. The competitive advantage increasingly lies in combining domain specialists with data, engineering and AI capabilities. Hyderabad’s ecosystem is particularly suited to this convergence.
  4. GCC Value Is Shifting from Execution to Capability Creation: The strongest signal is the nature of the work being assembled. Current Hyderabad roles span transformation, product, clinical programming, pharmacovigilance, cybersecurity and advanced technology. This suggests a broader shift from transactional delivery towards integrated capability ownership.
  5. Physical Scale Follows Strategic Mandate: The fact that the Hyderabad location has become Syneos Health’s largest office in Asia and third largest globally is significant. It indicates that the company is not treating India as a peripheral delivery location, but as a substantial component of its global capability architecture.

HYDERABAD’S LIFE SCIENCES + TECHNOLOGY ADVANTAGE

Hyderabad’s proposition for global life sciences companies is increasingly built around the intersection of two ecosystems: a deep pharmaceutical and biotechnology base and a growing technology, data and AI talent pool.

Syneos Health’s new hub strengthens this intersection. The development also adds another dimension to Hyderabad’s evolving GCC landscape. Rather than simply hosting technology delivery operations, the city is increasingly attracting domain-intensive global capability mandates where scientific expertise and technology need to operate together.

STRATEGIC OUTLOOK

Syneos Health’s Hyderabad expansion signals the emergence of a new class of life sciences capability centre, one where scientific expertise, clinical operations, data, engineering and AI converge. For Hyderabad, the opportunity extends beyond attracting another global healthcare player: it strengthens the city’s proposition as a location where complex, domain-intensive global capabilities can be built and scaled. For the wider Indian GCC ecosystem, it reinforces a larger trend, future capability centres will increasingly be defined not by the functions they support, but by the depth of expertise they can combine and the value they can create.

Curated by SSF Global

Tracking the shifts shaping GCCs, enterprise ecosystems, and the future of global business.

Share on      

SSF Global is a Global Community for Enterprise Function Leaders and serves as a research & advisory platform focused on Global Business Services (GBS), Global Capability Centres (GCCs), and the evolution of enterprise innovation in India and beyond. We track, publish, and partner in narratives that shape how capability centres transform into hubs of trust, intelligence, and sustainable growth. We also evaluate, assess and benchmark the GCCs for their performance, maturity and other parameters using our proprietary tools built from the knowledge gained from direct interaction with our members (GCCs & GBS).